| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7015315 | AKCEA THERAPS | Gapped oligonucleotides |
Mar, 2023
(1 year, 1 month ago) | |
| US7101993 | AKCEA THERAPS | Oligonucleotides containing 2′-O-modified purines |
Sep, 2023
(7 months ago) | |
| US8101743 | AKCEA THERAPS | Modulation of transthyretin expression |
Apr, 2025
(11 months from now) | |
| US9061044 | AKCEA THERAPS | Modulation of transthyretin expression |
Apr, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9399774 | AKCEA THERAPS | Modulation of transthyretin expression |
Apr, 2031
(7 years from now) | |
| US8697860 | AKCEA THERAPS | Diagnosis and treatment of disease |
Apr, 2031
(7 years from now) | |
Tegsedi is owned by Akcea Theraps.
Tegsedi contains Inotersen Sodium.
Tegsedi has a total of 6 drug patents out of which 2 drug patents have expired.
Expired drug patents of Tegsedi are:
- US7015315
- US7101993
Tegsedi was authorised for market use on 05 October, 2018.
Tegsedi is available in solution;subcutaneous dosage forms.
Tegsedi can be used as treatment of polyneuropathy of hereditary transthyretin amyloidosis.
Drug patent challenges can be filed against Tegsedi from 05 October, 2022.
The generics of Tegsedi are possible to be released after 29 April, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-212) | Oct 05, 2025 |
| New Chemical Entity Exclusivity(NCE) | Oct 05, 2023 |
Drugs and Companies using INOTERSEN SODIUM ingredient
NCE-1 date: 05 October, 2022
Market Authorisation Date: 05 October, 2018
Treatment: Treatment of polyneuropathy of hereditary transthyretin amyloidosis
Dosage: SOLUTION;SUBCUTANEOUS
TEGSEDI family patents
